Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
1 hedge funds and large institutions have $596 invested in Agile Therapeutics in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 20 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
95% less funds holding
Funds holding: 21 → 1 (-20)
100% less capital invested
Capital invested by funds: $496K → $596 (-$496K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 20
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$211K |
| 2 |
Renaissance Technologies
New York
|
-$115K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$39.9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$37.5K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$26.8K |
AGRX Hedge Fund Activity: Q1 2024 in Review
1 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q1 2024, worth a combined $596 — down 100% from $496K a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of AGRX and 0 opened new positions — a net loss of 20 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Armistice Capital, exiting entirely with an estimated $211K sold.
- 1 institutional investor held Agile Therapeutics (AGRX) as of Q1 2024, down from 21 in Q4 2023.
- Funds reported $596 of Agile Therapeutics stock for Q1 2024, down 100% quarter-over-quarter.
- 0 funds opened new Agile Therapeutics positions in Q1 2024 and 20 closed out, a net change of -20 holders.
- The largest Agile Therapeutics seller in Q1 2024 was Armistice Capital, an estimated $211K sold.
Based on aggregated 13F filings for Q1 2024.